Cancer mutations

References
Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-naïve patient: A report of three cases. Yamaguchi F, Fukuchi K, Yamazaki Y, Takayasu H, Tazawa S, Tateno H, Kato E, Wakabayashi A, Fujimori M, Iwasaki T, Hayashi M, Tsuchiya Y, Yamashita J, Takeda N, Kokubu F. Oncol Lett. 2014 Feb;7(2):357-360. PMID: #24396447#

p.Gly12Cys c.34G>T
COSMIC
http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=516
http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=1140136
http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=25878
http://cancer.sanger.ac.uk/cosmic/mutation/overview?id=513
The G12C KRAS mutation is a strong negative predictor for EGFR-TKI treatment, whereas other KRAS mutation types have not negatively predicted treatment efficacy compared with that for the wild-type KRAS (...)

EGFR-exon 19 insertion
Epidermal growth factor receptor (EGFR) genotyping is now standard in the management of advanced lung adenocarcinoma, as this biomarker predicts marked benefit from treatment with EGFR tyrosine kinase inhibitors (TKI).
EGFR exon 19 insertions are a poorly described family of EGFR mutations, and their association with EGFR-TKI sensitivity in lung adenocarcinoma is uncertain.
EGFR exon 19 insertions are a newly appreciated family of EGFR-TKI-sensitizing mutations, (...)

Tumors
KRAS-associated peripheral nerve sheath tumors KRAS-G12S-associated peripheral nerve sheath tumors (#23190154#). RAS pathway activation due to BRAF V600E and KRAS mutations is an important event in a subset of peripheral nerve sheath tumours not related to NF. (#23190154#) Benign (BPNST) and malignant (MPNST) peripheral nerve sheath tumours occur either sporadically or are related to neurofibromatosis (NF). The mechanisms involved are well known in NF-related tumours, but still (...)